Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
558
mi
from
Fridley, MN
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
558
mi
from
Fridley, MN
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
523
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1358
mi
from
Stony Brook, NY
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1358
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
976
mi
from
Winston-Salem, NC
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
976
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1383
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
522
mi
from
Austin, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
522
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
499
mi
from
College Station, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
499
mi
from
College Station, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1020
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1181
mi
from
Norfolk, VA
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1181
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
835
mi
from
Scottsdale, AZ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
835
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
UCLA David Geffen School of Medicine
1168
mi
from
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
UCLA David Geffen School of Medicine
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
1330
mi
from
Palo Alto, CA
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Michigan Health System
808
mi
from
Ann Arbor, MI
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Michigan Health System
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Rutgers Robert Wood Johnson Medical School
1265
mi
from
New Brunswick, NJ
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Rutgers Robert Wood Johnson Medical School
1265
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina Medical Center
1063
mi
from
Charleston, SC
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina Medical Center
1063
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
University of Utah Health Care
779
mi
from
Salt Lake City, UT
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
University of Utah Health Care
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Liverpool Hospital
8664
mi
from
Liverpool,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Liverpool Hospital
8664
mi
from
Liverpool,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
1127
mi
from
Washington,
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
1127
mi
from
Washington,
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
728
mi
from
Mobile, AL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
728
mi
from
Mobile, AL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
224
mi
from
Rogers, AR
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
224
mi
from
Rogers, AR
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1283
mi
from
Sacramento, CA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1319
mi
from
Miami, FL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1319
mi
from
Miami, FL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1306
mi
from
Miramar, FL
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1306
mi
from
Miramar, FL
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
798
mi
from
Newnan, GA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
798
mi
from
Newnan, GA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
657
mi
from
Louisville, KY
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
657
mi
from
Louisville, KY
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
521
mi
from
Albuquerque, NM
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
521
mi
from
Albuquerque, NM
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
989
mi
from
High Point, NC
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
989
mi
from
High Point, NC
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
903
mi
from
Beachwood, OH
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
903
mi
from
Beachwood, OH
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1386
mi
from
Portland, OR
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1386
mi
from
Portland, OR
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
821
mi
from
Chomutov,
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
821
mi
from
Chomutov,
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
1138
mi
from
San Diego, CA
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
1138
mi
from
San Diego, CA
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (8568)
1225
mi
from
New York, NY
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (8568)
1225
mi
from
New York, NY
Click here to add this to my saved trials
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
777
mi
from
Knoxville, TN
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
777
mi
from
Knoxville, TN
Click here to add this to my saved trials
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
1329
mi
from
Stanford, CA
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated:  12/31/1969
Sylvester Comprenhensive Cancer Center
1320
mi
from
Miami, FL
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated: 12/31/1969
Sylvester Comprenhensive Cancer Center
1320
mi
from
Miami, FL
Click here to add this to my saved trials
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated:  12/31/1969
University of Miami Hospital dermatology clinics
1320
mi
from
Miami, FL
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence
Status: Enrolling
Updated: 12/31/1969
University of Miami Hospital dermatology clinics
1320
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
Status: Enrolling
Updated:  12/31/1969
UCSF Dermatology
1181
mi
from
San Francisco, CA
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
Status: Enrolling
Updated: 12/31/1969
UCSF Dermatology
1181
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #129)
1179
mi
from
Encino, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #129)
1179
mi
from
Encino, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #136)
1178
mi
from
Los Angeles, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #136)
1178
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #147)
1280
mi
from
Sacramento, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #147)
1280
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #123)
1142
mi
from
San Diego, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #123)
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Warner Chilcott Research Site (Site #123)
1142
mi
from
San Diego, CA
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Warner Chilcott Research Site (Site #123)
1142
mi
from
San Diego, CA
Click here to add this to my saved trials